ABSTRACT The effect of protriptyline, a tricyclic antidepressant, on sleep architecture, nocturnal arterial oxygen desaturation, pulmonary function, and diurnal arterial blood gases was investigated in an open study of 14 patients with stable chronic obstructive lung disease. Daytime and overnight measurements were made before and 2 and 10 weeks after they started protriptyline (20 mg daily at bedtime). Two patients had to be excluded before the second visit and one before the third visit because of changes in treatment for their chest disease. Protriptyline caused mouth dryness in all patients and dysuria in six men. With protriptyline there were no significant changes in total sleep time, sleep period time, or the percentages of total sleep time occupied by stage I-II and stage III-IV sleep. The mean (SEM) percentage of total sleep time spent in rapid eye movement (REM) sleep decreased from 11 1 (1 7) to 4-6 (0 7) at two weeks and to 4-2 (1 -0) at 10 weeks. After protriptyline the time spent during sleep with an arterial oxygen saturation (Sao2) below each 5% increment above 65% was less than the baseline time; the lowest Sao2 (%) reached during sleep increased from 64 5 (1.7) to 72*7 (2
Introduction
Polysomnographic studies show that nocturnal arterial oxygen desaturation occurs frequently in patients with chronic obstructive lung disease,' and that oxygen desaturation is more pronounced during rapid eye movement (REM) sleep.2 Many factors, including change in airway resistance,3 ventilationperfusion abnormalities,4 and alveolar hypoventilation,5 may play a part in this fall in arterial oxygen saturation (Sao2). Whatever the mechanisms, repeated drops in Sao2 during sleep and the resulting rise in pulmonary vascular resistance6 may contribute to the development of pulmonary hypertension and cor pulmonale.
Continuous oxygen therapy remains the most effective treatment of sleep induced oxygen desaturation in chronic obstructive lung disease.7 Because the most severe falls in Sao2 occur during REM sleep, our hypothesis was that a reduction in time spent in this sleep stage would also limit sleep induced desaturation. As tricyclic antidepressants reduce the amount of time spent in REM sleep, we evaluated the effects of a non-sedating tricyclic drug, protriptyline, on diurnal pulmonary function, sleep architecture, and nocturnal oxygen desaturation in patients with stable chronic obstructive lung disease.
Methods

PATIENTS
We studied 14 outpatients with chronic obstructive 275 276 lung disease and a forced expiratory volume in one second (FEV,) less than 65% predicted, an FEV,/ forced vital capacity (FVC) ratio ofless than 65%, and an ambient air arterial oxygen tension (Pao2) while seated of 65 mm Hg* or less. Two patients were excluded before the second visit because the treatment for their chronic obstructive lung disease had been changed. Six patients were being followed for their lung disease in our institution and six had been referred for sleep studies (four for evaluation of the need for nocturnal oxygen therapy, two because the sleep apnoea syndrome was suspected). Clinical state and treatment were unchanged for at least four weeks preceding the start of the study. No subject was receiving diurnal or nocturnal oxygen therapy.
PROTOCOL
Subjects were evaluated on three occasions: before receiving protriptyline (baseline visit) and after two and 10 weeks of protriptyline treatment. At each visit pulmonary function tests and a polysomnographic study were carried out. After the baseline visit subjects took 20 mg protriptyline (Merck Frosst) once a day at bedtime. Patients were asked to bring their unconsumed medication at each visit.
The week 2 study was not carried out in two patients because of technical problems, and one patient who developed bronchopneumonia was not evaluated at 
Results
The mean (SEM) age ofthe 12 patients was 63 (1) years and weight (percentage of ideal body weight (120% (7 5) (table 1). Weight did not change during the study period. Each patient took protriptyline as prescribed. Dry mouth, dysuria, and constipation were the only side effects noted. No study was discontinued because of side effects, though the dose of protriptyline was reduced to 10 mg once a day after 2 weeks' treatment in two patients because of severe dryness of the mouth. The results at 10 weeks in these patients were similar to those of the other patients and have not been analysed separately. There was no significant change in lung volumes or forced expiratory flows during the study (table 2) The mean apnoea index was less than 5 in all patients for all visits. Sleep induced oxygen desaturation occurred in every subject, the largest fall in Sao2 occurring during REM sleep. Values for patient 12 were excluded from the analysis as the lowest baseline Sao2 value was undetermined (< 60%) and the week 10 visit was missed because of bronchopneumonia. Series, Cormier, Forge and to the right (fig 3) . Less time was spent with Sao2 below each saturation value at 2 and 10 weeks than at baseline for both REM and non-REM sleep; these decreases were significant for all 5% increments in Sao2 greater than 65%. Similar results were obtained when analysis was restricted to the nine patients who were studied at all three visits.
Discussion
Our findings indicate that protriptyline reduces the sleep induced fall in Sao2 and increases daytime Pao2. Most of our patients noted an improvement in sleep quality. This improvement could be related to the increase in the amount of time spent in slow wave sleep. Nocturnal oxygen therapy has also been reported to increase the percentage of stage III-IV sleep, although this increase was not significant."
As our protocol had no blind placebo arm, we have to consider whether the changes we observed could be related to spontaneous variations in Pao2 and sleep architecture. Although one inclusion criterion was a period of clinical stability for at least four weeks without any change in treatment for chronic obstructive lung disease, spontaneous improvement with time cannot be totally ruled out. We believe that it could not account for our findings for four reasons. (1) Four patients had pulmonary function tests, arterial blood gas measurements, and polysomnographic studies before the initial baseline visit (12 months before for patient 5, two months for patients I and 6, and two weeks before for patient 11). They were clinically stable throughout this period and none of the measurements we made had changed before they started protriptyline (the prestudy and the initial baseline Pao2 values were as follows: 58 and 57 mm Hg for patient 1, 61 and 57 mm Hg for patient 5, 57 and 54 mm Hg for patient 11, and 56 mm Hg at each visit for patient 6). (2) 
